Authors:
Orsolya Jójárt-Laczkovich Department of Pharmaceutical Technology, University of Szeged, Eötvös u. 6, 6720 Szeged, Hungary

Search for other papers by Orsolya Jójárt-Laczkovich in
Current site
Google Scholar
PubMed
Close
and
Piroska Szabó-Révész Department of Pharmaceutical Technology, University of Szeged, Eötvös u. 6, 6720 Szeged, Hungary

Search for other papers by Piroska Szabó-Révész in
Current site
Google Scholar
PubMed
Close
Open access

Abstract  

Amorphization is nowadays a method that is frequently applied in the pharmaceutical industry. The primary aim of this study is to achieve the amorphization of clopidogrel hydrogen sulphate as an active pharmaceutical ingredient (API) with various solvents and to choose the most suitable one. A secondary aim was to determine the glass-transition temperature (Tg) of this API and to classify it as a good or poor glass former. To investigate the amorphous form, differential scanning calorimetry, X-ray powder diffraction, and FT-IR analysis were applied. The melting point (Tm) was 177.4 °C (450.6 K), and Tg was determined to be 88.9 °C (362.1 K). The quotient Tg/Tm was 0.80, and this API was therefore classified as a good glass former.

  • Collapse
  • Expand

To see the editorial board, please visit the website of Springer Nature.

Manuscript Submission: HERE

For subscription options, please visit the website of Springer Nature.

Journal of Thermal Analysis and Calorimetry
Language English
Size A4
Year of
Foundation
1969
Volumes
per Year
1
Issues
per Year
24
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Springer Nature Switzerland AG
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
CH-6330 Cham, Switzerland Gewerbestrasse 11.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1388-6150 (Print)
ISSN 1588-2926 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jun 2024 0 5 2
Jul 2024 0 9 1
Aug 2024 0 15 3
Sep 2024 0 20 1
Oct 2024 0 59 2
Nov 2024 0 19 1
Dec 2024 0 1 1